Simfibrate
 | |
| Clinical data | |
|---|---|
| Trade names | Cholesolvin |
| Other names | 3-{[2-(4-Chlorophenoxy)-2-methylpropanoyl]oxy}propyl 2-(4-chlorophenoxy)-2-methylpropanoate |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.035.438 |
| Chemical and physical data | |
| Formula | C23H26Cl2O6 |
| Molar mass | 469.36 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Simfibrate (JAN/INN; trade name Cholesolvin) is a fibrate that has been used for the treatment of hyperlipidemia.[1][2] The substance is a double ester of clofibric acid with 1,3-propanediol which is cleaved in the body to one molecule of 1,3-propanediol and two molecules of clofibric acid which is the true lipid-lowering agent.
References
[edit]- ↑ Verma N (2016). "Introduction to Hyperlipidemia and its Treatment: A Review". International Journal of Current Pharmaceutical Research. 9: 6. doi:10.22159/ijcpr.2017v9i1.16616.
- ↑ Olsson AG, Orö L, Rössner S (1974). "Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate". Atherosclerosis. 19 (3): 407–15. doi:10.1016/S0021-9150(74)80005-5. PMID 4364073.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by adding missing information. |